Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Acton Pharmaceuticals, Inc. to be Acquired by Meda for up to $200 Million

Published: Friday, September 06, 2013
Last Updated: Friday, September 06, 2013
Bookmark and Share
Acton Pharmaceuticals, Inc. announced that it has entered into a definitive agreement under which the Company will be acquired by Meda in an all cash transaction.

The proposed transaction is subject to customary regulatory approvals and standard closing provisions.

Under the terms of the agreement, Meda will acquire 100% of Acton’s shares for $135 million plus $10 million in a contingent, near-term development milestone.  Acton will also receive certain sales-based milestones, which may bring the total potential acquisition value up to $200 million.

Acton is focused on the development of respiratory medicine and recently received U.S. Food and Drug Administration approval for AEROSPAN™ (flunisolide), for the treatment of asthma. AEROSPAN is a HFA-propelled inhaled corticosteroid (ICS) and is the only approved HFA inhaler in its class to incorporate a built-in spacer device, which assists in the delivery of the medicine to the lungs.  The value of the U.S. single-entity ICS market is approaching $2 billion with more than 12 million prescriptions written each year.
 
AEROSPAN Inhalation Aerosol is an orally inhaled corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 6 years of age and older.

Acton was founded in March 2008 by John Simon, Chief Executive Officer and Daniel Kreisler, President & Chief Operating Officer of Acton.

"Through this transaction with Meda, AEROSPAN will now be commercialized by a company with one of the leading respiratory focused sales forces in the U.S.,” commented Daniel Kreisler.  “We strongly believe this will accelerate the prescribing of this unique inhaled steroid product so we can achieve our goal of making AEROSPAN one of the leading therapies in the $2 billion U.S. inhaled steroid market.”

John Simon continued, “We are excited to enter into this agreement with Meda, a leading global pharmaceutical company.  Meda’s experience marketing respiratory products combined with their significant track record of success makes them extremely well-suited to launch AEROSPAN to respiratory and pediatric physicians in the U.S.”

Scott Carter, a partner at Sequoia Capital and a member of Acton’s Board of Directors said, “We are very fortunate to partner with Acton Pharmaceuticals.  Sequoia Capital recognizes and applauds the excellence of this highly experienced management team who has driven the company to tremendous success.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
How To Keep Your Rice Arsenic-Free
Researchers at Queen’s University Belfast have made a breakthrough in discovering how to lower worrying levels of arsenic in rice that is eaten all over the world.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Computer Model Could Explain how Simple Molecules Took First Step Toward Life
Two Brookhaven researchers developed theoretical model to explain the origins of self-replicating molecules.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!